De Aizpurua H J, French M B, Chosich N, Harrison L C
Burnet Clinical Research Unit, Walter and Eliza Hall Institute of Medical Research, Royal Melbourne Hospital, Parkville, Australia.
J Autoimmun. 1994 Oct;7(5):643-53. doi: 10.1006/jaut.1994.1049.
Autoantibodies to glutamic acid decarboxylase (GAD) are present in humans before and after the onset of clinical insulin-dependent diabetes (IDD). The non-obese diabetic (NOD) mouse, a model of human IDD, develops mononuclear cell infiltration of the pancreatic islets ('insulitis') associated particularly in females with T cell-mediated destruction of the islet beta cells. In NOD mice of both sexes we detected serum antibodies to GAD (GAD Ab) that precipitate mouse brain GAD enzymatic activity. Antibodies in NOD sera also precipitate a M(r) 65,000 protein from Triton X-100 extracts of 35S-methionine-labelled NOD islets, identical in size to that precipitated by a monoclonal antibody to GAD. GAD Ab were not detected in other mouse strains. There were significant differences in the frequency, level and age at initial detection of GAD Ab between females of the NOD/Lt and NOD/WEHI lines, previously shown to have a higher and lower incidence of diabetes, respectively. Comparing NOD/Lt (n = 26) and NOD/WEHI (n = 20) females, in which diabetes occurred in 38% and 20% by 150 days, the frequency of elevated GAD Ab was 50 vs. 80%, the mean maximum GAD Ab level 21.1 vs. 30.6% and the mean age at which GAD Ab were first detected 94 vs. 45 days. No significant differences in these parameters were observed between male mice of either line. There was a significant negative correlation between the level of GAD Ab and the degree of insulitis in female mice from both lines. GAD Ab were not a prerequisite for the development of diabetes. In 7 of 10 female mice the onset of diabetes was preceded by a decrease of GAD Ab levels into the normal range. These findings indicate that, while GAD is a target of autoimmunity in the NOD mouse, GAD Ab do not necessarily correlate with the development of diabetes. Indeed, the difference between the two NOD lines and the inverse relationship with insulitis suggests that a strong humoral response to GAD may be associated with a less destructive pathology, as proposed in humans 'at-risk' for IDD.
在临床胰岛素依赖型糖尿病(IDD)发病之前及之后,人体中均存在谷氨酸脱羧酶(GAD)自身抗体。非肥胖型糖尿病(NOD)小鼠是人类IDD的一种模型,会出现胰岛的单核细胞浸润(“胰岛炎”),在雌性小鼠中尤其与T细胞介导的胰岛β细胞破坏有关。在两性的NOD小鼠中,我们检测到血清中存在能沉淀小鼠脑GAD酶活性的GAD抗体(GAD Ab)。NOD血清中的抗体还能从经35S - 蛋氨酸标记的NOD胰岛的Triton X - 100提取物中沉淀出一种分子量为65,000的蛋白质,其大小与GAD单克隆抗体沉淀出的蛋白质相同。在其他小鼠品系中未检测到GAD Ab。之前已显示分别具有较高和较低糖尿病发病率的NOD/Lt和NOD/WEHI品系的雌性小鼠,在GAD Ab的初始检测频率、水平及年龄方面存在显著差异。比较NOD/Lt(n = 26)和NOD/WEHI(n = 20)雌性小鼠,到150天时糖尿病发生率分别为38%和20%,GAD Ab升高的频率分别为50%和80%,GAD Ab的平均最大水平分别为21.1%和30.6%,首次检测到GAD Ab的平均年龄分别为94天和45天。在任一品系的雄性小鼠之间未观察到这些参数的显著差异。来自两个品系的雌性小鼠中,GAD Ab水平与胰岛炎程度之间存在显著负相关。GAD Ab并非糖尿病发生的先决条件。在10只雌性小鼠中有7只,糖尿病发病前GAD Ab水平降至正常范围。这些发现表明,虽然GAD是NOD小鼠自身免疫的一个靶点,但GAD Ab不一定与糖尿病的发生相关。实际上,两个NOD品系之间的差异以及与胰岛炎的反向关系表明,对GAD的强烈体液反应可能与破坏性较小的病理状况相关,正如在患IDD“风险”人群中所提出的那样。